- Reported positive topline induction data for SPY003 in Phase 2 SKYLINE trial, completing PoC for three IBD monotherapies.
- SKYLINE Part B enrollment progressing ahead of schedule with results expected Q3 2027.
- Balance sheet shows over $1.09B in total assets and cash/equivalents of $82.7M.
Why is $SYRE moving today? · SEC 8-K archive
$SYRE SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $SYRE: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $SYRE filing catalyst
Why did $SYRE trigger an AI stock catalyst alert?
$SYRE triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Spyre Therapeutics Reports Positive Phase 2 SPY003 Data and Q3 Results. Key points: - Reported positive topline induction data for SPY003 in Phase 2 SKYLINE trial, completing PoC for three IBD monotherapies. - SKYLINE Part B enrollment progressing ahead of schedule with results expected Q3 2027. - Balance sheet shows over $1.09B in total assets and cash/equivalents of $82.7M.
How did $SYRE stock react after the SEC filing?
After the SEC 8-K for $SYRE, observed market reaction: T0 price $99.27. Past moves do not guarantee future results.
Where can I get real-time $SYRE SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $SYRE via Telegram and the VIP Web Terminal from €10/month.